Appendix B to Part 627 - Resource List for Immunoprophylaxis of Personnel at Risk

B-1. Recommendations for Immunoprophylaxis of Personnel at RiskDescription of diseaseProductRecommended for use in Source of productAnthraxInactivated vaccinePersonnel working regularly with cultures, diagnostic materials, or infected animalsUSAMRIID.1BotulismPentavalent toxoid (A,B,C,D,E) (IND).2Personnel working regularly with cultures or toxinCDC.3CholeraInactivated vaccinePersonnel working regularly with large volumes or high concentrations of infectious materialsCommercially available.Diphtheria Tetanus (Adult)Combined toxoidAll laboratory and animal care personnel irrespective of agents handledCommercially available.Eastern equine encephalitis (EEE)Inactivated vaccine (IND) 2Personnel who work directly and regularly with EEE in the laboratoryUSAMRIID.1Hepatitis AImmune Serum Globulin [ISG (Human)]Animal care personnel working directly with chimpanzees naturally or experimentally infected with Hepatitis A virusCommercially available.Hepatitis BSerum-derived or recombinant vaccinePersonnel working regularly with human blood and blood componentsCommercially available.InfluenzaInactivated vaccine(Vaccines prepared from earlier isolated strains may be of little value in personnel working with recent isolates from humans or animals)Commercially available.Japanese EncephalitisInactivated vaccine (IND) 2Personnel who work directly and regularly with JE virus in the laboratoryCDC.3MeaslesLive attenuated virus vaccineMeasles-susceptible personnel working with the agent or potentially infectious clinical materialsCommercially available.Meningococcal MeningitisPurified polysaccharide vaccinePersonnel working regularly with large volumes or high concentrations of infectious materials (does not protect against infection with group B meningococcus)Commercially available.PlagueInactivated vaccinePersonnel working regularly with cultures of Yersinia pestis or infected rodents or fleasCommercially available.PoliomyelitisInactivated (IPV) and live attenuated (OPV) vaccinesPolio-susceptible personnel working with the virus or entering laboratories or animal rooms where the virus is in useCommercially available.Pox viruses (Vaccinia, Cowpox, or Monkey Pox viruses)Live (lyophilized) vaccinia virusPersonnel working with orthopox viruses transmissible to humans, with animals infected with these agents, and persons entering areas where these viruses are in useCDC.3Q Fever (Phase II) vaccineInactivated (IND) 2Personnel who have no demonstrable sensitivity to Q fever antigen and who are at high risk of exposure to infectious materials or animalsUSAMRIID.1RabiesHuman diploid line cell inactivated vaccinePersonnel working with all strains of rabies virus, with infected animals, or persons entering areas where these activities are conductedCommercially available.Rift Valley FeverInactivated virus vaccine (IND) 2All laboratory and animal care personnel working with the agent or infected animals and all personnel entering laboratories or animal rooms when the agent is in useUSAMRIID.1RubellaLive attenuated virus vaccineRubella-susceptible personnel, especially women, working with “wild” strains or in areas where these viruses are in useCommercially available.TuberculosisLive, attenuated (BCG) bacterial vaccineBCG vaccine ordinarily is not used in laboratory personnel in the U.SCommercially available.TularemiaLive attenuated bacterial vaccine (IND).2Personnel working regularly with cultures or infected animals or persons entering areas where the agent of infected animals are in useUSAMRIID.1TyphoidInactivated vaccinePersonnel who have no demonstrated sensitivity to the vaccine and who work regularly with culturesCommercially available.Venezuelan equine (VEE) encephalitisLive attenuated (TC83) viral vaccine (IND).2Personnel working with VEE and the Equine Cabassou, Everglades, Mucambo, and Tonate viruses, or who enter areas where these viruses are in useUSAMRIID.1Western equine encephalitis (WEE)Inactivated vaccine (IND) 2 with WEE virusPersonnel who work directly and regularly in the laboratoryUSAMRIID.1Yellow FeverLive attenuated (17D) virus vaccinePersonnel working with virulent and avirulent strains of Yellow Fever virusCommercially available.1 For information, contact: United States Army Medical Materiel Development Activity, Fort Detrick, Frederick, MD 21701, telephone: [phone] Investigational New Drug (IND).3 Clinical Medicine Branch, Division of Host Factors, Center for Infectious Disease, Centers for Disease Control, Atlanta, GA 30333, telephone: [phone].Source: Adapted from recommendations of the PHS Immunization Practices Advisory Committee and Biosafety in Microbiological and Biomedical Laboratories.